Phase I trial of RG 2833 in patients with Friedreich's ataxia.
Phase of Trial: Phase I
Latest Information Update: 04 May 2012
At a glance
- Drugs RG 2833 (Primary)
- Indications Friedreich's ataxia
- Focus Adverse reactions; Pharmacokinetics
- 15 Mar 2012 Status changed from planning to recruiting, according to a Repligen Corporation media release.
- 02 May 2011 New trial record